Initial dosing strategies for long-acting injectable risperidone [5]

Journal of Clinical Psychiatry

Volumn 67, Issue 8, 2006, Pages 1310-1311

  Viner, Mark W ^a   Matuszak, Jeremy M ^a   Knight, Linda J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

CLINICAL FEATURE; HUMAN; LETTER; MENTAL DISEASE; OUTPATIENT; PHYSICIAN; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 33748952465     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0821e     Document Type: Letter

References (2)

1. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-1257
2. Kane JM, Eerdekens M, Lindenmayer JP. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132